Trade Tempest Therapeutics, Inc. - TPST CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.36 |
| Open | 3.28 |
| 1-Year Change | 51.85% |
| Day's Range | 3.2 - 3.33 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 10, 2024 | 3.21 | -0.25 | -7.23% | 3.46 | 3.46 | 3.14 |
| May 9, 2024 | 3.42 | -0.01 | -0.29% | 3.43 | 3.53 | 3.42 |
| May 8, 2024 | 3.44 | -0.05 | -1.43% | 3.49 | 3.49 | 3.41 |
| May 7, 2024 | 3.60 | -0.08 | -2.17% | 3.68 | 3.74 | 3.57 |
| May 6, 2024 | 3.69 | 0.02 | 0.54% | 3.67 | 3.72 | 3.58 |
| May 3, 2024 | 3.66 | 0.09 | 2.52% | 3.57 | 3.72 | 3.52 |
| May 2, 2024 | 3.52 | -0.11 | -3.03% | 3.63 | 3.72 | 3.43 |
| May 1, 2024 | 3.59 | 0.19 | 5.59% | 3.40 | 3.64 | 3.38 |
| Apr 30, 2024 | 3.43 | 0.05 | 1.48% | 3.38 | 3.51 | 3.37 |
| Apr 29, 2024 | 3.42 | -0.09 | -2.56% | 3.51 | 3.67 | 3.42 |
| Apr 26, 2024 | 3.50 | 0.01 | 0.29% | 3.49 | 3.61 | 3.36 |
| Apr 25, 2024 | 3.45 | 0.13 | 3.92% | 3.32 | 3.45 | 3.29 |
| Apr 24, 2024 | 3.40 | -0.01 | -0.29% | 3.41 | 3.53 | 3.31 |
| Apr 23, 2024 | 3.39 | 0.20 | 6.27% | 3.19 | 3.43 | 3.18 |
| Apr 22, 2024 | 3.20 | 0.12 | 3.90% | 3.08 | 3.25 | 3.03 |
| Apr 19, 2024 | 3.08 | -0.05 | -1.60% | 3.13 | 3.23 | 3.04 |
| Apr 18, 2024 | 3.15 | -0.08 | -2.48% | 3.23 | 3.31 | 3.14 |
| Apr 17, 2024 | 3.23 | -0.02 | -0.62% | 3.25 | 3.31 | 3.19 |
| Apr 16, 2024 | 3.31 | 0.01 | 0.30% | 3.30 | 3.40 | 3.19 |
| Apr 15, 2024 | 3.31 | -0.26 | -7.28% | 3.57 | 3.60 | 3.29 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Tempest Therapeutics, Inc. Company profile
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Tempest Therapeutics Inc revenues was not reported. Net loss decreased 29% to $20.5M. Lower net loss reflects Research and development - Balancing decrease of 23% to $12.2M (expense), Other general and administrative decrease of 32% to $6.6M (expense), Stock-based Compensation in SGA decrease of 75% to $600K (expense).
Equity composition
Common Stock $.001 par, 11/12, 100M auth., 14,262,276 issd., Insider Own approx.1%.
| Industry: | Biotechnology & Medical Research (NEC) |
2000 Sierra Point Parkway
Suite 400
BRISBANE
CALIFORNIA 94005
US
News
Disinflation resumes in the US as CPI drops in April
The rate of growth in US consumer prices dropped in April leading markets to price in more chances of rate cuts from the Fed
11:24, 16 May 2024
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com